anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Arbutus Biopharma · pitchdeck

Arbutus Biopharma | Investor Presentation Deck | 26 slides

26 pages · 5 arc beats · 3 loops

Pitchdeck Download JSON
Unlock

Arbutus Biopharma | Investor Presentation Deck | 26 slides

Arbutus Biopharma · 2024-06
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 9 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem Statement 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Traction 5 slides 100% 5/5 slides 100% 5/5 slides · 22 hits
— 0/5 slides
80% 4/5 slides 20% 1/5 slides 100% 5/5 slides
— 0/5 slides
Roadmap 1 slides 100% 1/1 slides 100% 1/1 slides · 3 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides
— 0/1 slides
Key Takeaways 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

26
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
present_solution
Open slide detailLoop · Golden Circle
04
The slide uses a grid layout to present six distinct value propositions for the company.summarize
Open slide detailLoop · Golden Circle
05
The slide uses a standard pharmaceutical pipeline visualization format.plan_implementation
Open slide detailBeat · Roadmap
06
The slide uses a four-column layout to structure the disease landscape.frame_problem
Open slide detail
07
Uses a Venn/concentric circle diagram to show the funnel from total infected to diagnosed to treated.frame_problem
Open slide detailBeat · Problem StatementLoop · Aha Moment
08
The slide uses a process-oriented flow diagram to explain the therapeutic strategy.present_solution
Open slide detailBeat · SolutionLoop · Aha Moment
09
transition
Open slide detail
10
The slide highlights the mechanism of action and key benefits of the drug candidate.present_solution
Open slide detail
11
summarize
Open slide detailBeat · Key Takeaways
12
The slide outlines a clinical trial protocol with specific patient counts (n=43, 12, 13, 8, 10) and timeline milestones (weeks 1, 24, 28, 40, 52).plan_implementation
Open slide detail
13
Data presented at EASL 2024. Includes specific patient counts and percentages for Cohorts A1 and A2.show_traction
Open slide detailBeat · Traction
14
Data presented at EASL 2024. LLOQ = 0.05 IU/mL.show_traction
Open slide detailBeat · Traction
15
The slide outlines two parallel study arms involving Imdusiran, VTP-300, NA, and Nivolumab.plan_implementation
Open slide detailBeat · Traction
16
Data presented at EASL 2024. Includes stacked bar charts for threshold achievement and line chart for mean levels over 72 weeks.show_traction
Open slide detailBeat · Traction
17
Data presented at EASL 2024. Includes pie charts comparing Group A and Group B across three metrics: time off NA therapy, HBV DNA levels, and HBsAg levels.show_traction
Open slide detailBeat · Traction
18
The slide outlines a clinical trial structure with three cohorts (A, B, C) and a follow-up period, totaling 48 weeks.plan_implementation
Open slide detail
19
The slide details a specific licensing deal with financial terms and geographic scope.show_traction
Open slide detail
20
transition
Open slide detail
21
The slide uses a three-column layout to explain the scientific basis and product profile of the drug candidate.present_solution
Open slide detail
22
Includes both in vitro (IFN-y fold increase) and in vivo (MC38 tumor model) efficacy data.show_traction
Open slide detail
23
The slide uses a process flow diagram to illustrate the sequential dosing cohorts in a clinical trial setting.plan_implementation
Open slide detail
24
Includes a diagram showing the split of royalties/damages between Arbutus and Genevant.other
Open slide detail
25
The slide uses checkmarks to indicate completed milestones within the 1H 2024 period.plan_implementation
Open slide detail
26
state_next_steps
Open slide detail